SCHEMBL231979

SCHEMBL231979

O=C(O)c1cc(F)ccn1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 8/20 0.61
ALDH1A1 P00352 3/20 0.61
ASPH Q12797 3/20 0.61
KDM8 Q8N371 3/20 0.61
KDM5A P29375 2/20 0.61
KDM3A Q9Y4C1 2/20 0.61
KDM6B O15054 1/20 0.61
TET3 O43151 1/20 0.61
KDM4A O75164 1/20 0.61
BBOX1 O75936 1/20 0.61
MAPT P10636 1/20 0.61
KDM5C P41229 1/20 0.61
KDM4D Q6B0I6 1/20 0.61
TET2 Q6N021 1/20 0.61
ALKBH5 Q6P6C2 1/20 0.61
KDM7A Q6ZMT4 1/20 0.61
TET1 Q8NFU7 1/20 0.61
EGLN2 Q96KS0 1/20 0.61
FTO Q9C0B1 1/20 0.61
EGLN1 Q9GZT9 1/20 0.61

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29954072 1.00 KDM4E (0.61) KDM4EALDH1A1ASPHKDM8KDM5A
SCHEMBL2275018 0.98 KDM4E (0.59) KDM4EALDH1A1ASPHKDM8KDM5A
SCHEMBL3223370 0.81 KMO (0.65) KDM4EALDH1A1ASPHKDM8KDM5A
SCHEMBL23874595 0.81 GRM5 (0.43) KDM4EALDH1A1ASPHKDM8KDM5A
SCHEMBL30004144 0.81 ALDH1A1 (0.50) KDM4EALDH1A1ASPHKDM8KDM5A
SCHEMBL30668214 0.81 ADORA3 (0.45) KDM4EALDH1A1ASPHKDM8KDM5A
SCHEMBL7692385 0.81 ADORA3 (0.45) KDM4EALDH1A1ASPHKDM8KDM5A
SCHEMBL1612977 0.81 ALDH1A1 (0.50) KDM4EALDH1A1ASPHKDM8KDM5A
SCHEMBL24572141 0.80 KMO (0.62) KDM4EALDH1A1ASPHKDM8KDM5A
SCHEMBL30800092 0.79 KMO (0.71) KDM4EALDH1A1ASPHKDM8KDM5A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 136 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117836306-A Galactose glycoside derivatives as galectin-3 inhibitors 株式会社蒂奥姆生物 2024-04-05 CN claimed
CN-112552233-A Synthetic method of 2-amino-4-fluoropyridine 镇江卡博医药科技有限公司 2021-03-26 CN claimed
CN-102105437-A Adamantyl diamide derivatives and uses of same LUNDBECK & CO AS H 2011-06-22 CN claimed
US-20100022546-A1 ADAMANTYL DIAMIDE DERIVATIVES AND USES OF SAME H. LUNDBECK A/S (DK) 2010-01-28 US claimed
EP-4724435-A1 BIFUNCTIONAL AZINES CONJOGATES AS SELECTIVE DEGRADERS OF SMARCA2 AND THERAPEUTIC USES THEREOF Nurix Therapeutics, Inc. (US) 2026-04-15 EP disclosed
US-20260083851-A1 POTENT ASGPR-BINDING HETEROBIFUNCTIONAL COMPOUNDS FOR THE DEGRADATION OF IMMUNOGLOBULINS AND OTHER PROTEINS AVILAR THERAPEUTICS, INC. (US) 2026-03-26 US disclosed
EP-4713320-A2 BCAT2 INHIBITORS Agios Pharmaceuticals, Inc. (US) 2026-03-25 EP disclosed
EP-3710428-B1 MODULATORS OF THE INTEGRATED STRESS PATHWAY CALICO LIFE SCIENCES LLC (US) 2026-03-25 EP disclosed
US-12559462-B2 Pyrimidine derivatives as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto ARENA PHARMACEUTICALS, INC. (US) 2026-02-24 US disclosed
US-20250270172-A1 Pyrimidine Derivatives As Modulators of the 5-HT2A Serotonin Receptor Useful For The Treatment of Disorders Related Thereto ARENA PHARMACEUTICALS, INC. (US) 2025-08-28 US disclosed
EP-4236937-B1 PYRIMIDINE DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO ARENA PHARM INC (US) 2025-07-23 EP disclosed
EP-4572759-A2 THIAZOLE DERIVATIVES FOR THERAPEUTIC USE Nimml Institute (US) 2025-06-25 EP disclosed
WO-2011050316-A1 MGLUR4 ALLOSTERIC POTENTIATORS, COMPOSITIONS, AND METHODS OF TREATING NEUROLOGICAL DYSFUNCTION VANDERBILT UNIVERSITY (US) 2011-04-28 WO disclosed
WO-2011035174-A1 SUBSTITUTED HETEROARYLAMINE CARBOXAMIDE ANALOGS AS MGLUR5 NEGATIVE ALLOSTERIC MODULATORS AND METHODS OF MAKING AND USING THE SAME VANDERBILT UNIVERSITY (US) 2011-03-24 WO disclosed
WO-2010066357-A1 BENZOTHIAZOLE AMIDES FOR DETECTION OF AMYLOID BETA BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2010-06-17 WO disclosed
WO-2010066357-A1 BENZOTHIAZOLE AMIDES FOR DETECTION OF AMYLOID BETA BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2010-06-17 WO disclosed
US-6337368-B1 WATER INSOLUBLE CARRIERS WITH P-NITROBENZOIC ACID, AROMATIC AMINES, AMIDES, SULFONAMIDES AND HYDRAZIDES KANEKA CORPORATION (JP) 2002-01-08 US disclosed
EP-1008383-A1 LIPOPROTEIN ADSORBENT AND LIPOPROTEIN ADSORBER MADE WITH THE USE OF THE SAME KANEKA CORPORATION (JP) 2000-06-14 EP disclosed
US-5582817-A ORGANOZINC COMPOUNDS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 1996-12-10 US disclosed
EP-0583479-A1 REMEDY FOR DERMATOPATHY AND METALLOTHIONEIN INDUCER OTSUKA PHARMACEUTICAL CO., LTD. (JP) 1994-02-23 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250270172-A1 Pyrimidine Derivatives As Modulators of the 5-HT2A Serotonin Receptor Useful For The Treatment of Disorders Related Thereto HTR2A, HTR5A, HTR1A KDM4E 3934/4885ALDH1A1 768/4885ASPH 1161/4885
US-20260083851-A1 POTENT ASGPR-BINDING HETEROBIFUNCTIONAL COMPOUNDS FOR THE DEGRADATION OF IMMUNOGLOBULINS AND OTHER PROTEINS ASGR1, FCGR2A, FCGR3B KDM4E 4281/4885ALDH1A1 2349/4885ASPH 1493/4885
US-12559462-B2 Pyrimidine derivatives as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto HTR2C, HTR1A, HTR2A KDM4E 4301/4885ALDH1A1 873/4885ASPH 3113/4885
US-20100022546-A1 ADAMANTYL DIAMIDE DERIVATIVES AND USES OF SAME QDPR, ADM2, PDE3B KDM4E 2749/4885ALDH1A1 105/4885ASPH 358/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.